Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PRA
PRA logo

PRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Proassurance Corp (PRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
24.660
1 Day change
0.24%
52 Week Range
24.850
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Proassurance Corp (PRA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signs, the lack of significant catalysts, weak revenue growth, and neutral trading trends suggest that holding off on this investment might be prudent. The stock's short-term trend also indicates potential downside risk in the next month.

Technical Analysis

The MACD is slightly positive at 0.0124, indicating mild bullish momentum. The RSI is neutral at 55.378, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 24.734 and 24.843, with support at 24.383 and 24.274. However, the stock's short-term trend suggests a potential decline in the next week (-1.53%) and month (-6.99%).

Options Data

Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
2
Buy
10

Positive Catalysts

  • Net income and EPS showed significant YoY growth in Q4 2025, up 106.38% and 106.45%, respectively.

Neutral/Negative Catalysts

  • No significant news, insider activity, or hedge fund trends. The stock's short-term trend indicates potential downside risk.

Financial Performance

In Q4 2025, revenue dropped to $272.95M (-5.54% YoY), but net income increased to $33.37M (+106.38% YoY) and EPS rose to 0.64 (+106.45% YoY). Gross margin remained unchanged.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast PRA stock price to rise
Analyst Rating
0
Wall Street analysts forecast PRA stock price to rise
Buy
Hold
Sell
0
Current: 24.600
sliders
Low
0
Averages
0
High
0
0
Current: 24.600
sliders
Low
0
Averages
0
High
0
Piper Sandler
Paul Newsome
Neutral
maintain
$18 -> $25
AI Analysis
2025-05-08
Reason
Piper Sandler
Paul Newsome
Price Target
$18 -> $25
AI Analysis
2025-05-08
maintain
Neutral
Reason
Piper Sandler analyst Paul Newsome raised the firm's price target on ProAssurance to $25 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported a miss versus PSC and consensus. Underwriting results were worse than expected, but top-line results were higher than Piper expected and premiums in the company's medical malpractice business were stable. Bottom-line results were impacted by non-operating items totaling $12.6M related to its merger with The Doctors Company, the firm adds.

People Also Watch